



Simplify SARS-CoV-2 testing

The BD Veritor™ Plus System
Rapid, reliable SARS-CoV-2 testing at the
point of care

The portable, easy-to-use BD Veritor™ Plus System provides reliable
SARS-CoV-2 results in 15 minutes



Be ready for SARS-CoV-2 testing

When your patients are in need of fast, reliable SARS-CoV-2 testing, turn to the BD Veritor™ Plus System. Offering dependable results at the point of care, in a simple-to-operate, portable instrument.



Simplify the testing process

- Easy operation and 1-button functionality may potentially reduce manual test processing errors
- Enables intuitive sample processing with prefilled, unitised tubes color-coded by reagent or assay type



Achieve fast, reliable results

- Displays easy-to-read digital results for SARS-CoV-2 in 15 minutes
- Records results on secured internal drive
- Advanced particle technology enhances sensitivity by using a proprietary process to produce highly stable, modified colloidal metal particles, helping improve test performance*
- Adaptive read technology helps improve specificity to reduce false-positive results by compensating for background and nonspecific binding



Provide workflow efficiency

- Adapts easily to your workflow by offering 2 operational modes
 - **Walk away:** Test device is inserted immediately into Analyser, enabling staff to multitask while sample incubates
 - **Analyse now:** Test device is inserted after incubation time is complete, allowing batches of samples to be tested



Provide result traceability

- Download and display LOT number, Patient/specimen ID, Operator ID and test records with BD Veritor™ InfoScan module
- Offers result-printing capabilities via USB port



Clinical Performance¹

Positive Percent Agreement (PPA)	Negative Percent Agreement (NPA)
93.5%**	99.3%**
(95% Confidence Interval (C.I.), 79.3%-98.2%)	(95% Confidence Interval (C.I.), 96.4%-99.9%)

Negative results do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient's recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19, and confirmed with a molecular assay, if necessary, for patient management.

Ordering information	Cat. no.	Qty.
BD Veritor™ System for Rapid Detection of SARS-CoV-2	256089	30 tests
BD Veritor™ Plus System Analyzer	256066	1
Other BD Veritor™ related products		
BD Veritor™ System Flu A+B Moderately complex	256041	30 tests
BD Veritor™ System Flu A+B CLIA-waived kit	256045	30 tests
BD Veritor™ System RSV CLIA-waived kit	256038	30 tests
BD Veritor™ System RSV Moderately complex	256042	30 tests
BD Veritor™ System Group A Strep CLIA-waived kit	256040	30 tests
BD Veritor™ InfoScan module 1	256068	1
USB printer cable 1	443907	1

*in comparison to visually read tests

**clinical performance data taken from Study 2 in the package insert. Performance established with patients reporting two or more self-reported symptoms.

1. BD Veritor System for Rapid Detection of SARS-CoV-2 package insert. Franklin Lakes, NJ: Becton, Dickinson and Company.

BD - Europe, Terre Bonne Park – A4, Route de Crassier 17, 1262 Eysins, Switzerland

bd.com/VeritorSystem-EU

Unless otherwise indicated, all products are CE-marked in compliance with the European In Vitro Diagnostic Medical Devices Directive 98/79/EC.

BD, the BD Logo and Veritor are trademarks of Becton, Dickinson and Company or its affiliates.

All other trademarks are the property of their respective owners. © 2020 BD. All rights reserved. XEUR5439-20-01

